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Abstract: Antibiotic treatment in paediatric rhinosinusitis is still a matter of debate, as the
current guidelines have been drafted mainly based on clinical studies published before 2013.
Recent modifications in the epidemiological basis of the disease might mean that current treatments
are not completely adequate considering the evolving microbiological profile of the disease.
The present paper reviews the role of systemic antibiotics in children with acute (ARS), chronic
(CRS), recurrent (RARS), and complicated acute (CoARS) rhinosinusitis. A total of 14 studies
(including 3 prospective non-randomised studies, 8 retrospective studies, and 3 prospective
randomised studies) of the 115 initially identified papers were included in this review, corresponding
to 13,425 patients. Five papers dealt with ARS, four papers with RARS or CRS, and five papers with
CoARS; the remaining papers included patients with either ARS or CRS. Data about the effectiveness
of antibiotic treatment in children with ARC, CRS, and CoARS is scarce, as only three randomised
controlled trials have been published in the last decade, with contrasting results. There is an urgent
need for dedicated controlled trials not only to test the actual clinical benefits deriving from the routine
use of systemic antibiotics in different categories of patients but also to compare the effectiveness
of various therapeutic protocols in terms of the type of antibacterial molecules and the duration
of treatment.
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1. Introduction
Rhinosinusitis (RS) is a frequent condition in the paediatric population [1]. Acute RS (ARS)
is generally secondary to bacterial superinfection after an acute upper respiratory tract infection
(URTI) [1]. It is a relatively common condition, as it has been reported to develop in approximately
6.5% of children with upper respiratory tract infection [2], accounting for more than 20% of antibiotic
prescriptions in children [1].
Medical protocols in children with ARS mainly include amoxicillin alone or in combination with
clavulanic acid [3], but given that ARS generally follows a viral URTI, with signs and symptoms
frequently overlapping, antibiotic treatment is probably overused, with possible side effects and
concerns for the development of bacterial resistance and increasing health costs.
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Chronic rhinosinusitis (CRS) is defined by the persistence of symptoms suggestive of nasal
and sinusal inflammation lasting more than 12 weeks [4]. In some children with CRS, symptoms
are not controlled despite adequate medical treatment based on guidelines. This subset of patients
may be scheduled among those with the so-called paediatric severe chronic upper airway disease
(P-SCUAD) [5].
CRS is a heterogeneous spectrum of disease, and different phenotypes and endotypes
(i.e., biological subtypes defined by corresponding biomarkers and peculiar responsiveness to some
medical treatments) may be identified [6]. Causative factors include allergic and non-allergic rhinitis,
airway pollution, smoke exposure [7], bacterial biofilm [8,9], and anatomic anomalies impairing the
sinonasal drainage. Underlying systemic diseases (such as cystic fibrosis, primary ciliary dyskinesia,
immune defects) may also predispose to CRS [10,11]. The mainstream treatment of paediatric CRS
consists of maximal medical therapy including 3 to 6 weeks of broad-spectrum systemic antibiotics
with adjunctive therapies [12,13]. However, a recent survey evaluating the management of CRS in
children in different paediatric healthcare providers [14] documented that the antibiotic protocols
used are not completely homogeneous, with the most frequently used being amoxicillin (72%),
amoxicillin-calvulanic acid (98%), cefdinir (73%), and azithromycin (15%), and that the length of
treatment is generally 10 (70%) or 14 (17%) days. In the case of incomplete recovery after maximal
medical therapy, surgery should be offered [15].
Complicated disease (CoARS) develops when the infection spreads to the nearby anatomic
structures, including the orbits and the brain, possibly resulting in blindness and life-threatening
sequelae [16]. Sinonasal-related orbital infections (SROIs) are the most frequent complications among
children [1]: they typically follow an acute ethmoiditis and generally affect children younger than
5 years old [17]. SROIs comprise a large spectrum of clinical manifestations that can involve either the
eyelids and adnexa anterior to the orbital septum or, more dangerously, the orbital structures placed
behind it. Therefore, we can distinguish between pre-septal complications (i.e., periorbital cellulitis
(POC) (Figure 1A,B) and post-septal complications that include orbital cellulitis (OC), sub-periosteal
abscess (SPA), and orbital abscess (OA) [18]. Intra-cranial life-threatening complications are cerebral
abscess, cavernous sinus thrombosis, and meningitis. Current evidence suggests that parenteral
medical treatment should be considered first in patients with POC and OC [16]; scheduled protocols
include clindamycin plus third-generation cephalosporin, vancomycin with or without meropenem,
ampicillin-sulbactam, and third-generation cephalosporin plus metronidazole [19–27]. In the case of
SPA, OA, or intracranial extension, urgent surgical drainage should be offered, too.
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 2 of 13 
 
scheduled among those with the so-call d pae iatric severe chronic up r airway disease (P-SCUAD) 
[5]. 
CRS is a heterogeneous spectrum of disease, and different phenotypes and endotypes (i.e., 
biological subtypes defined by corresponding biomarkers and peculiar responsiveness to some 
medical treatments) may be identified [6]. Causative factors include allergic and non-allergic rhinitis, 
airway pollution, smoke exposure [7], bacterial biofilm [8,9], and anatomic anomalies impairing the 
sinonasal drainage. Underlying systemic diseases (such as cystic fibrosis, primary ciliary dyskinesia, 
immune defects) may also predispose to CRS [10,11]. The mainstream treatment of paediatric CRS 
consists of maximal medical therapy including 3 to 6 weeks of broad-spectrum systemic antibiotics 
with adjunctive therapies [12,13]. However, a recent survey evaluating the management of CRS in 
ch dren in different paediatric healthcare providers [14] documented that the tibiotic protocols 
used are not completely homogeneous, with the most frequently used being amoxicillin (72%), 
amoxicillin-calvulanic acid (98%), cefdinir (73%), and azithromycin (15%), and that the length of 
treatment is generally 10 (70%) or 14 (17%) days. In the case of incomplete recovery after maximal 
medical therapy, surgery should be offered [15]. 
Complicated disease (CoARS) develops when the infection spreads to the nearby anatomic 
structures, including the orbits and the brain, possibly resulting in blindness and life-threatening 
sequelae [16]. Sinonasal-related orbital infections (SROIs) are the most frequent complications among 
children [1]: they typically follow an acute ethmoiditis and generally affect children younger than 5 
years old [17]. SROIs comprise a large spectrum of clinical manifestations that can involve either the 
eyelids and adn xa anterior to the orbital septum or, more dangerously, he orb tal structures p ac d 
behind it. Therefore, we can distinguish betwee  pre-septal complications (i.e., periorbital cellulitis 
(POC) (Figure 1A,B) and post-septal complications that include orbital cellulitis (OC), sub-periosteal 
abscess (SPA), and orbital abscess (OA) [18]. Intra-cranial life-threatening complications are cerebral 
abscess, cavernous sinus thrombosis, and meningitis. Current evidence suggests that parenteral 
medical treatment should be considered first in patients with POC and OC [16]; scheduled protocols 
include clindamycin plus third-generation cephalosporin, vancomycin with or without meropenem, 
ampicillin-sulbactam, and third-generation cephalosporin plus metronidazole [19–27]. In the case of 
SPA, OA, or intracranial extension, urgent surgical drainage should be offered, too. 
 
Figure 1. A 4-year-old girl with left periorbital cellulitis related to acute ethmoiditis before (A) and 
after (B) treatment with cefotaxime. 
2. Microbiological Basis 
Bacteriological analysis is highly suggested in order to adjust the antibiotic treatment. 
Polymicrobial or culture-negative specimens are not so rare; sterile samples are obtained in 25–30% 
of cases. In recent years, there has been an increase in the reports of fungal invasion accompanying 
rhinosinusitis. These forms are connected with several promoting factors such as diabetes, 
steroidotherapy, and immunosuppression [28]. 
The most common germs are Streptococcus species, anaerobes, and Staphylococcus Aureus 
[25,26,29]. In the medical literature, the aerobic species cited as being among the most prevalent 
include S. aureus, H. influenza, S. pneumoniae, S. viridans, and M. catarrhalis. The most frequently 
reported anaerobes include Peptostreptococcus, Prevotella, Fusobacterium, Propionibacterium, and 
Bacteroides. A recent classification [2] has elucidated the change in microbial population compared to 
the past and the microbial aetiological differences existing between acute and chronic rhinosinusitis 
Figure 1. A 4-year-old girl with left periorbital cell litis related to acute ethmoiditis before (A) and
after (B) treatment with cefotaxime.
2. Microbiological Basis
Bacteriological analysis is highly suggested in order to adjust the antibiotic treatment.
Polymicrobial or culture-negative specimens are not so rare; sterile samples are obtained in
25–30% of cases. In recent years, there has been an increase in the reports of fungal invasion
accompanying rhinosinusitis. These forms are connected with several promoting factors such as
diabetes, steroidotherapy, and immunosuppression [28].
The most common germs are Streptococcus species, anaerobes, and Staphylococcus Aureus [25,26,29].
In the me ical literature, the aerobic s ecies cit d as being among the most prevalent include S. aureus,
H. influenza, S. p eumoniae, S. viridans, and M. atarrhalis. The most frequently reported naerobes include
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Peptostreptococcus, Prevotella, Fusobacterium, Propionibacterium, and Bacteroides. A recent classification [2]
has elucidated the change in microbial population compared to the past and the microbial aetiological
differences existing between acute and chronic rhinosinusitis in children. Recent publications have
emphasised S. milleri as the most common pathogen in patients with complicated sinusitis [30–32].
Several studies have suggested a link between biofilm and rhinosinusitis. Yet, little is known
about the pathophysiology and role of biofilm in the complicated forms of rhinosinusitis, and no
studies on the factors that determine the formation and persistence of biofilms on the sinonasal mucosa
and connected sites have clearly demonstrated its role.
Biofilms are morphologically characterised as three-dimensional complexes of bacteria enclosed
in a self-produced extra-cellular matrix of polysaccharides, nucleic acids, proteins, and extra-cellular
DNA. Most of the biofilm mass consists of water; the rest is made up of extra-cellular matrix and
bacterial cells [33].
It is likely that biofilms occur in many cases of rhinosinusitis in complicated forms, but a
methodology for processing clinical samples is currently lacking. Several groups have suggested using
confocal scanning laser microscopy and fluorescent in situ hybridisation probes as the ‘gold standard’
for biofilm imaging. However, this should be combined with other microbiological tests, such as the
traditional culture techniques used to identify and quantify pathogens [34].
Given the difficulty of studying biofilms in a viable tissue culture or even in animals, only a few
studies have successfully evaluated their interaction with their host. Using human broncho-epithelial
cells, Starner et al. showed that H. influenzae biofilms stimulate an inflammatory response by increasing
the levels of NF-kB, IL-8, TNF-α, and the macrophage inflammatory protein MIP-3α.
In order to further investigate the behaviour of sinonasal mucosa biofilms, some studies have
used animal models. Perloff and Palmer found that maxillary sinusitis induced by P. aeruginosa in
rabbits was associated with biofilm formation on the sinus mucosa at different endpoints up to the
20th day of infection, and substantially promoted sinus ostium occlusion [35,36].
Many scientists are more convinced that the main negative result in rhinosinusitis patients with
biofilm-endowed bacteria is the high degree of insusceptibility to several antibiotics as well as to the
host immune mechanisms [37].
Chiu et al. [38] developed an animal biofilm sinusitis model in which an in-dwelling irrigation
catheter is used to screen the anti-biofilm activity of antibiotics and/or surfactants. This model may
be useful in the future development of topical drugs and for assessing the efficacy and safety of
anti-biofilm agents such as anti-quorum-sensing drugs [39].
Familiarity with the microbiology of rhinosinusitis and its complications is of great importance
for selecting empirical antimicrobial therapy. The selection of the appropriate antimicrobial agents is
generally a first-line mandatory approach to obtain optimal efficacy (knowing microbes for choosing
the best antibiotic). The main pathogenic factor that concurs with the negative outcome of the
disease is certainly the biofilm, which necessarily requires a different diagnostic and therapeutic
approach. The therapeutic intervention should act in two possible ways: (A) by inhibiting biofilm
formation, or (B) by eradicating the biofilm already formed. Further studies are necessary in order
to investigate the mechanisms underlying biofilm formation and the related cellular and humoral
defence responses, as well as those factors driving the host-biofilm interactions. This will require the
development of new and more feasible methods for detecting biofilm that should eventually lead to
new therapeutic perspectives.
3. Aim of Study and Methods
Antibiotic treatment in paediatric RS is still a matter of debate because, despite the availability of
guidelines on management strategies, the current guidelines mainly refer to clinical studies published
before 2013. The microbiological profile of RS has evolved significantly due to the introduction of
the pneumococcal conjugate vaccine (PCV) and changes in antibiotic susceptibility, which makes
previously established guidelines inadequate for managing the current clinical manifestations.
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The present paper discusses the role of systemic antibiotics in children with acute (ARS),
chronic (CRS), recurrent (RARS), and complicated acute (CoARS) rhinosinusitis. Relevant original
papers concerning the use of systemic antibiotic treatments in children with RS were selected by
Sara Torretta after a MEDLINE search (accessed via PubMed) based on the terms “antibiotic and
rhinosinusitis and children” on 21 March 2019. The articles searched aimed to evaluate the effectiveness
and safety of systemic antibiotic treatments in children with ARC, RARS/CRS, and CoARS, as attested
by the reported success rate in achieving clinical or symptomatic improvement, and related failure and
side effects rate when available.
Consideration was only given to original clinical studies on human subjects published in the
English language in peer-reviewed journals from March 2009. Animal studies, reviews, and case series
including children with systemic disease (cystic fibrosis, primary ciliary dyskinesia, immunological
defects) or adult patients were excluded.
The reference lists of identified articles were subsequently reviewed to ensure that all of the
selected papers were truly relevant and to identify any articles that had possibly been overlooked.
4. Results
A total of 14 papers (including 3 prospective non-randomised studies, 8 retrospective studies,
and 3 prospective randomised studies) of the 115 initially identified papers were included in this
review, corresponding to 13,425 patients (Figure 2) [2,40–51]. Five papers dealt with ARS, four papers
with RARS or CRS, and five papers with CoARS (in one study, patients with either ARS or CRS were
included) [44].
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• Acute Rhinosinusitis
Among the five identified papers on systemic antibiotic treatments in children with ARS
(and corresponding to 13,000 patients in total), we found one prospective non-randomised,
two prospective randomised, and two retrospective studies. The studies were not homogeneous in
terms of intervention or clinical outcomes. Table 1 shows the main characteristics of the selected case
series and relate res lts.
The study published by de Moor et al. [40] was a large retrospective assessment using the General
Practice Research database from the United Kingdom to evaluate the comparative effectiveness of
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nasal steroid spray versus systemic antibiotics versus combined treatment in both paediatric and adult
patients (12,679). It was found that the use of nasal steroid spray (alone or associated with antibiotic)
was more effective in reducing rhinosinusitis-related medical encounters and decreasing the use of
related prescriptions as compared to antibiotics alone.
The randomised, double-blind placebo-controlled trial by Wald et al. [2] evaluated the effectiveness
of antibiotic therapy with amoxicillin (90 mg/kg/day) plus potassium clavulanate (6.4 mg/kg/day) in
two doses compared to placebo in 56 children with ARS. They found a significantly increased cure rate
and reduced failure rate in the study group compared to controls; on the other hand, side effects were
more frequent in children receiving antibiotics.
More recently, a prospective, randomised, blind-controlled trial by Ragab et al. [41] compared the
effectiveness of amoxicillin (100 mg/kg/day) plus 0.9% nasal saline irrigations against placebo plus
0.9% nasal saline irrigations on 62 patients. They found that the clinical cure (defined as complete
recovery of all symptoms and signs of infection) was slightly, although not significantly, increased
in the study group compared to controls. No difference between the groups was detected in terms
of subjective improvement (attested by the nasal symptoms score and the standardised Paediatric
Rhinoconjunctivitis Quality of Life Questionnaire), but the side effects rate increased in the control
group compared to the placebo group.
• Recurrent Acute Rhinosinusitis and Chronic Rhinosinusitis
Among the four identified papers (and corresponding to 263 patients in total), we found one
retrospective, one prospective randomised, and two prospective non-randomised trials. The studies
were not homogeneous in terms of interventions or clinical outcomes. Table 2 shows the main
characteristics of the selected case series and related results.
Two papers [42,43] assessing the reduction in sinonasal infectious exacerbations in children with
RARS documented a positive effect of the treatment protocol in most cases. In particular, Veskitkul
et al. [43] published a randomised double-blind placebo-controlled trial in 60 children receiving
azithromycin 5 mg/kg/day for 3 days a week for 12 months or placebo. They reported a significantly
reduced number of acute infectious episodes in the study group compared to the placebo group, and a
significant improvement in terms of symptom and adjunctive medication scores compared to baseline
in the treatment group but not in the control group.
Two papers [44,45] on the effectiveness of systemic antibiotics using different therapeutic protocols
in children with CRS found a symptomatic improvement in most cases. Shin et al. [45] attributed
clinical failure to the presence of increased serum eosinophils or eosinophilic cationic protein levels.
No comparative evaluations of different therapeutic protocols were performed.
• Complicated Acute Rhinosinusitis
All five of the identified papers (corresponding to 162 patients in total) were retrospective studies.
The studies were not homogeneous in terms of interventions or clinical outcomes. Table 3 shows the
main characteristics of the selected case series and related results.
Two papers [46,47] reported clinical outcomes in children with sinonasal-related subperiosteal
orbital abscesses taking systemic antibiotics (with different therapeutic protocols) with or without
complementary surgery. A positive response to conservative treatment in children with a small
abscess (i.e., volume < 0.5 mL) was documented by Gavriel et al. [46]. On the contrary, Ketenci et
al. [47] reported the development of recurrences in more than 8% of cases, and the occurrence of
life-threatening events including unilateral blindness (5.5%), intracranial abscess formation, and death
(2.8%) despite systemic antibiotic and surgical treatment.
Schupper et al. [48] retrospectively assessed clinical outcomes in children with sinonasal-related
intracranial complications and documented recurrences with abscess reaccumulation in approximately
37% of patients receiving vancomycin, meropenem, or ceftriaxone with surgery.
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Table 1. Results of the included studies on ARS.
Author, Year Pts Category No. of Pts;Age (Years) Study Design Interventions Outcomes Failures and Side Effects
Wald et al., 2009 [2] 56; 66 ± 30 months Prospectiverandomised
Amoxicillin (90 mg/kg/day) with
potassium clavulanate
(6.4 mg/kg/day) in two doses
(50%) vs. placebo
Children receiving antibiotics were more
likely to be cured (50% vs. 14%;
p = 0.010) and less likely to have
treatment failure (14% vs. 68%; p < 0.001)
compared to placebo
Adverse events * more frequently
occurred in treatment compared
to placebo group (44% vs. 14%;
p = 0.014);
* self-limiting diarrhoea
De Moor et al., 2012
[40] 12679; 12–75 Retrospective
Mometasone furoato nasal spray
(MNS) vs. MNS plus antibiotic vs.
antibiotic
MNS (alone or in combination with
antibiotic) significantly reduced the risk
of rhinosinusitis-related medical
encounters compared to antibiotic alone
Poachanukoon et al.,
2012 [44]
ARS (103) and
CRS (51) 154; 5.9 ± 3.3
Prospective
non-randomised
Amoxicillin-clavulanic acid (54.5%),
cefditoren pivoxil (33.8%) for
14.6 ± 3.8 days (ARS) or 22.3 ± 5.0
days (CRS); intravenous antibiotic in
5.8% of cases (77.8% with ARS)
Symptomatic improvement in ARS
group after 14.6 days of treatment on
average and in CRS group after 22.3 days
of treatment on average; no one
underwent surgery
Wan et al., 2015 [49] Allergic rhinitis in50% 100; 15 ± 1.7 Retrospective
Amoxicillin-clavulanic acid vs.
amoxicillin-clavulanic acid plus
intranasal corticosteroid vs. placebo
Symptom improvement in 92% and 88%
of patients receiving
amoxicillin-clavulanic acid with and
without allergic rhinitis, respectively,
compared to symptom improvement in
84% and 96% of patients receiving
amoxicillin-clavulanic acid plus
intranasal corticosteroid with and
without allergic rhinitis, respectively;
symptomatic improvement in 30% of
placebo group
Ragab et al., 2015
[41]
62; 5.4 ± 2.3 and
4.6 ± 2.0
Prospective
randomised
Amoxicillin 100 mg/kg/day, three
times a day, plus nasal saline
irrigations vs. placebo plus nasal
saline irrigations
Clinical recovery in 83.9% and 71% of
patients respectively belonging to study
and control group (not significant);
clinical improvement in 3% and 6% of
patients respectively belonging to study
and control group
Adverse events in 58.1% * and
25.8% of patients respectively
belonging to study and control
group (p = 0.005); * including
diarrhoea (29.0%), abdominal
pain (16.1%), and nausea (6.0%)
ARS = acute rhinosinusitis; CRS = chronic rhinosinusitis; Pts = patients.
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Table 2. Results of the included studies on RARS or CRS.
Author, Year Pts Category No. of Pts; Age(Years) Study Design Interventions Outcomes Failures and Side Effects
Poachanukoon et al.,
2012 [44]
ARS (103) and CRS
(51) 154; 5.9 ± 3.3
Prospective
non-randomised
Amoxicillin-clavulanic acid (54.5%),
cefditoren pivoxil (33.8%) for
14.6 ± 3.8 days (ARS) or 22.3 ± 5.0 days
(CRS); intravenous antibiotic in 5.8% of
cases (77.8% with ARS)
Symptomatic improvement in ARS
group after 14.6 days of treatment on
average and in CRS group after
22.3 days of treatment on average;
no one underwent surgery
Shin et al., 2015 [45]
CRS (62.1%
non-respondents and
37.9% respondents)
58 with CRS; 5.8 ± 3.0
and 5.6 ± 2.7
Prospective
non-randomised
Amoxicillin (90 mg/kg/day) with
clavulanic acid (6.4 mg/kg/day),
second-or third-generation
cephalosporines for 12 weeks
Symptomatic, clinical, or
radiological recovery in 62.1%
Lack of response to antibiotic
treatment was significantly
related to increased total
eosinophilic count and serum
eosinophilic cationic
protein levels
Veskitkul et al., 2015
[42]
RARS (IgG subclass
deficiency in 78.7%) 94; 7.7 ± 2.6 Retrospective
Oral antibiotic prophylaxis in 61.5% *
(± adenotonsillectomy, allergen
immunotherapy, gentamicin nasal
irrigations, intravenous
immunoglobulins); * amoxicillin
or azithromycin
Symptomatic improvement in 80%
of patients receiving antibiotic
Veskitkul et al., 2017
[43] RARS 60; 5–15
Prospective
randomised
Azithromycin 5 mg/kg/day for 3 days a
week for 12 months
Number of acute episodes
significantly reduced in children
receiving antibiotic compared to
controls with a number needed to
treat = 2; subjective improvement
and reduced adjunctive medication
in study but not control group
RARS = recurrent acute rhinosinusitis; CRS = chronic rhinosinusitis; Pts = patients.
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Table 3. Results of the included studies on complicated acute rhinosinusitis (CoARS).
Author, Year Pts Category No. of Pts; Age(Years) Study Design Interventions Outcomes Failures and Side Effects
Kristo et al.,
2009 [50]
Orbital
complications 20; 6.4 (8.0–12.4) Retrospective
Parenteral antibiotic * (surgery in 10%);
* cefuroxime (80.0%), clindamycin
(10.0%), combined (10.0%)
Complete recovery in 100%
Hurley et al.,
2011 [51] SPA 42; <9 years Retrospective
Parenteral antibiotic: combined therapy
with either amoxicillin-sulbactam or a
third-generation cephalosporin, and
either clindamycin or vancomycin for
2–8 days, followed by
amoxicillin-clavulanate for 2–3 weeks
Complete recovery in 97.6% One patient readmitted andunderwent surgery
Gavriel et al.,
2011 [46] SPA 48; 4.0 ± 3.5 Retrospective
Parenteral antibiotic * (surgery in 47.6%);
* amoxicillin-clavulanic acid (83.3%),
ceftriaxone (10.0%), clindamycin plus
metronidazole (8.3%), cefuroxime (2%)
Children with an abscess >0.5 mL
should be candidates for surgery;
conservative treatment can be
considered only in those with
smaller abscess without visual
impairment
Ketenci et al.,
2013 [47] SPA
36; 3–76 (47.2%
< 10 years) Retrospective
Ampicillin with or without
metronidazole or clindamycin as first
choice (ampicillin in 64.0%, multiple
antibiotics * in 36.0%); *
ampicillin-sulbactam, clindamycin,
sulperazone, metronidazole; 3–9 days
for medial, 6–10 days for superior, and
3–4 days for inferior SPA location
Visual recovery in 47.21%; partial
visual recovery in 5.5%
Unilateral blindness in 5.5%. Early
recurrences in 5.5% (second surgery);
late recurrence in 2.8% (first surgery);
intracranial abscess with fatal outcome
in 2.8% (repeated surgery)
Schupper et al.,
2018 [48]
Intracranial
complications 16; 5–17 Retrospective
Parenteral antibiotic (vancomycin,
meropenem, and ceftriaxone) with sinus
surgery (plus craniotomy in 68.0%)
Abscess reaccumulation in 37.5%.
Allergic reaction (12.0% to ceftriaxone,
vamcomycin), meropenem-induced
neutropenia (6.0%)
SPA = subperiosteal orbital abscess; Pts = patients.
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5. Discussion
Systemic antibiotic therapy in paediatric ARS is currently based on the guidelines of the Infectious
Disease Society of America and American Academy of Paediatric, respectively published in 2012 and
2013 [52,53]. The former suggests amoxicillin-clavulanate (rather that amoxicillin alone) as an empiric
antibiotic treatment in children with ARS (at the dosage of 90 mg/kg/day in two doses in children
with severe disease or with a risk factor for invasive penicillin-nonsusceptible S. pneumoniaea) for
10–14 days [52]; the latter also includes high-dose amoxicillin as a first-line treatment for 10–28 days [53]
(Table 4). More recently, Wald et al. [54] proposed a regular dose (45 mg/kg/day in two doses) of
amoxicillin-clavulanate as the preferred treatment for paediatric ARS; this approach results from the
observation that, since the licensure of 7-valent PCV (PCV7), and then 10-valent PCV (PCV10) and
13-valent PCV (PCV13), the rate of nasopharyngeal colonisation with vaccine strains of S. pneumoniaea
has declined, and although new serotypes have emerged, the prevalence of penicillin-resistant
S. pneumoniae is low, so the use of high-dose amoxicillin is not mandatory. On the other hand,
the subsequent increase in H. influenza and M. catarrhalis (able to produce beta-lactamase) as causative
germs requires association with clavulanic acid in order to enhance beta-lactamase coverage.
Table 4. Indications for systemic antibiotic therapy in paediatric ARS based on guidelines.
Author, Year Document Recommendation
Chow et al.,
2012 [52] IDSA guideline
Amoxicillin-clavulanate. In patients with risk factors *,
amoxicillin-clavulanate (90 mg/kg/day in two doses) or
third-generation cephalosporin plus clindamycin for 10–14 days.
In the case of non-type I hypersensitivity, third-generation
cephalosporin plus clindamycin, doxycycline
Wald et al.,
2013 [53] AAP guidelines
Amoxicillin or amoxicillin-clavulanate in children with severe
onset or worsening for 10–28 days. Intravenous or
intramuscular ceftriaxone (50 mg/kg) if oral therapy is not
possible. In the case of non-type I hypersensitivity cefdinir,
cefuroxime; in the case of type-I hypersensitivity, cefdinir,
cefuroxime or cefixime plus clindamycin
Wald and de
Muri, 2018 [54] Expert opinion Amoxicillin-clavulanate (45 mg/kg/day) in two doses
IDSA = Infectious Diseases Society of America; AAP = American academy of paediatrics; * patients who received
previous antibiotic, with severe infection, attendance to school, systemic disease, living in endemic area for invasive
penicillin-nonsusceptible S. pneumoniae, younger than 2 years.
In 2014, a panel composed of nine representative otolaryngologists produced a consensus statement
about the diagnostic and therapeutic management of CRS [55]. They did not reach agreement about
the appropriate antibiotic treatment including a minimum of 10 consecutive days, but they agreed on
the superiority of a 20-day compared to a 10-day treatment regimen of systemic antibiotic treatment
and on the fact that culture-directed antibiotic therapy may improve clinical outcomes in patients
not responding to empirical treatment for CRS [55]. More recently, a review [56] about the role of
antibiotic treatment in paediatric CRS identified three possible alternative oral treatment regimens
effective against polymicrobial infections possibly substained by beta-lactamase-producing aerobic
and anaerobic pathogens. They included amoxicillin-calvulanate as the first-line option (at the dosage
of 45 mg/kg/day divided into two doses; the 90-mg/kg/day dose should be used in children from
geographic areas with a high endemic rate of invasive penicillin-nonsusceptible S. pneumoniae and in
those with severe infection, attending daycare, younger than 2 years, with immune defects, recent
hospitalisation, or antibiotic assumption) or clindamycin (20–40 mg/kg/day divided into a dose
every 6–8 h) in penicillin-allergic children. Refractory cases should be treated with metronidazole
(30–50 mg/kg/day divided into three daily doses) plus one molecule that is active against aerobic and
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facultative bacteria (cefuroxime axetil, cefdinir, cefpodoxime proxetil, azithromycin, clarithromycin,
trimethoprim-sulfamethoxazole) [56].
Our review documents the paucity of high-quality evidence deriving from papers published in the
last decade about the antibiotic management of children with RS. In particular, no randomised controlled
studies of good quality have been recently conducted to test the applicability of antibiotic protocols in
children with CRS or CoARS. Only two randomised controlled trials on paediatric ARS were published
in the last 10 years [2,41], both of them evaluating the effect of amoxicillin (with or without clavulanic
acid 100 mg/kg/day) with or without complementary therapy, with contrasting results. In fact, the study
by Wald et al. [2] favoured treatment, while a more recent study by Ragab et al. [41] found no significant
difference in the cure rate between children receiving the antibiotic (plus nasal saline irrigations) and
those receiving the placebo (plus nasal saline irrigations). A further study retrospectively comparing
the cure rate in ARS children (with or without concomitant allergic rhinitis) undergoing different
therapeutic protocols found better results in children receiving amoxicillin-clavulanic acid (with or
without intranasal corticosteroids) compared to those receiving a placebo. As a whole, the reported
recovery rates are greater in the antibiotic groups (50–94%) compared to placebo groups (14–71%),
and side effects were more common in the former group (44–58% vs. 14–26%).
In addition, despite knowing about the involvement of bacterial biofilms in the pathogenesis of RS
in children and that they may impair the effectiveness of traditional systemic antibiotic treatments [8,9],
not one of the clinical studies reviewed here reported the diagnosis of biofilms. Accordingly, we suggest
incorporating biofilm detection in patients with chronic or recurrent disease, either by the means of
electron microscopy analysis on bioptic mucosal specimens taken during surgery in child candidates
for adenoidectomy or endoscopic sinus surgery after the failure of maximal medical treatment, or by
the means of a simpler spectrophotometric evaluation performed on endoscopically-collected middle
meatal swabs. Moreover, we strongly advocate dedicated clinical studies aimed at evaluating the
responsiveness of different medical protocols in patients with biofilm-related CRS or RARS.
6. Conclusions
Today, antibiotic treatment in paediatric RS is mainly based on guidelines published in 2012
and 2013, which might no longer be completely appropriate, given the supposed change in bacterial
etiology after the introduction of the pneumococcal conjugate vaccine, promoting the emergence of
non-vaccinal serotypes, and the absence of dedicated microbiological studies evaluating the role of
new emerging pathogens and related resistance.
There are very few recent studies on the effectiveness of antibiotic treatment in children with ARC,
CRS, and CoARS, as only three randomised controlled trials have been published in the last decade,
with contrasting results.
There is an urgent need for dedicated controlled trials not only to test the actual clinical benefits
of the routine use of systemic antibiotics in different categories of patients but also to compare the
effectiveness of various therapeutic protocols in terms of the kind of antibacterial molecules and
duration of treatment.
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